Endo International (NASDAQ:ENDP) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) in a research report issued on Monday. The firm set a “hold” rating on the stock.

Endo International Trading Down 5.0 %

Shares of ENDP opened at $0.29 on Monday. Endo International has a 12 month low of $0.28 and a 12 month high of $7.07. The firm has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $1.34. The stock has a market capitalization of $68.80 million, a price-to-earnings ratio of -0.03 and a beta of 1.15.

Institutional Trading of Endo International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its position in Endo International by 161.7% during the first quarter. New York State Common Retirement Fund now owns 426,139 shares of the company’s stock worth $984,000 after acquiring an additional 263,322 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Endo International by 303.0% in the second quarter. Russell Investments Group Ltd. now owns 1,137,391 shares of the company’s stock valued at $527,000 after purchasing an additional 855,145 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its position in shares of Endo International by 34.0% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 438,499 shares of the company’s stock valued at $1,013,000 after purchasing an additional 111,380 shares during the period. State of Tennessee Treasury Department raised its position in shares of Endo International by 44.5% in the first quarter. State of Tennessee Treasury Department now owns 217,468 shares of the company’s stock valued at $502,000 after purchasing an additional 66,966 shares during the period. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Endo International by 36.3% in the first quarter. Sterling Investment Advisors Ltd. now owns 37,515 shares of the company’s stock valued at $87,000 after purchasing an additional 10,000 shares during the period. 80.39% of the stock is owned by institutional investors.

Endo International Company Profile

(Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Featured Stories

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.